Whitney Notaro | Vice President-Investor Relations |
Doug Hirsch | Co-Founders & Co-Chief Executive Officer |
Trevor Bezdek | Co-Founders & Co-Chief Executive Officer |
Karsten Voermann | Chief Financial Officer |
Glen Santangelo | Jefferies |
Sandy Draper | Guggenheim Partners |
Stephanie Davis | SVB Securities |
Michael Cherny | BofA |
Craig Hettenbach | Morgan Stanley |
Mark Mahaney | Evercore ISI |
Eric Sheridan | Goldman Sachs |
Doug Anmuth | JPMorgan |
Charles Rhyee | Cowen |
John Ransom | Raymond James |
George Hill | Deutsche Bank |
Stan Berenshteyn | Wells Fargo |
Steven Valiquette | Barclays |
Jonathan Yong | Credit Suisse |
Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx Second Quarter 2022 Earnings Call.
As a reminder, today's conference call is being recorded. I would now like to introduce your host for today's call, Whitney Notaro, Vice President of Investor Relations. Ms. Notaro, you may begin.